Benzinga

España
Italia
대한민국
日本
Français
Benzinga Edge
Benzinga Research
Benzinga Pro

  • Get Benzinga Pro
  • Data & APIs
  • Events
  • Premarket
  • Advertise
Contribute
España
Italia
대한민국
日本
Français

Benzinga

  • Premium Services
  • Financial News
    Latest
    Earnings
    Guidance
    Dividends
    M&A
    Buybacks
    Interviews
    Management
    Offerings
    IPOs
    Insider Trades
    Biotech/FDA
    Politics
    Healthcare
    Small-Cap
  • Markets
    Pre-Market
    After Hours
    Movers
    ETFs
    Options
    Cryptocurrency
    Commodities
    Bonds
    Futures
    Mining
    Real Estate
    Volatility
  • Ratings
    Analyst Color
    Downgrades
    Upgrades
    Initiations
    Price Target
  • Investing Ideas
    Trade Ideas
    Long Ideas
    Short Ideas
    Technicals
    Analyst Ratings
    Analyst Color
    Latest Rumors
    Whisper Index
    Stock of the Day
    Best Stocks & ETFs
    Best Penny Stocks
    Best S&P 500 ETFs
    Best Swing Trade Stocks
    Best Blue Chip Stocks
    Best High-Volume Penny Stocks
    Best Small Cap ETFs
    Best Stocks to Day Trade
    Best REITs
  • Money
    Investing
    Cryptocurrency
    Mortgage
    Insurance
    Yield
    Personal Finance
    Forex
    Startup Investing
    Real Estate Investing
    Prop Trading
    Credit Cards
    Stock Brokers
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
Unusual Options Activity Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Screeners
Stock Screener
Top Momentum Stocks
Top Quality Stocks
Top Value Stocks
Top Growth Stocks
Compare Best Stocks
Best Momentum Stocks
Best Quality Stocks
Best Value Stocks
Best Growth Stocks
Connect With Us
facebookinstagramlinkedintwitteryoutubeblueskymastodon
About Benzinga
  • About Us
  • Careers
  • Advertise
  • Contact Us
Market Resources
  • Advanced Stock Screener Tools
  • Options Trading Chain Analysis
  • Comprehensive Earnings Calendar
  • Dividend Investor Calendar and Alerts
  • Economic Calendar and Market Events
  • IPO Calendar and New Listings
  • Market Outlook and Analysis
  • Wall Street Analyst Ratings and Targets
Trading Tools & Education
  • Benzinga Pro Trading Platform
  • Options Trading Strategies and News
  • Stock Market Trading Ideas and Analysis
  • Technical Analysis Charts and Indicators
  • Fundamental Analysis and Valuation
  • Day Trading Guides and Strategies
  • Live Investor Events
  • Pre-market Stock Analysis and News
  • Cryptocurrency Market Analysis and News
Ring the Bell

A newsletter built for market enthusiasts by market enthusiasts. Top stories, top movers, and trade ideas delivered to your inbox every weekday before and after the market closes.

  • Terms & Conditions
  • Do Not Sell My Personal Data/Privacy Policy
  • Disclaimer
  • Service Status
  • Sitemap
© 2026 Benzinga | All Rights Reserved
November 2, 2017 4:30 PM 19 min read

AquaBounty Technologies, Inc. Results for the quarter ended September 30, 2017

by Globe Newswire
Follow

MAYNARD, Mass., Nov. 02, 2017 (GLOBE NEWSWIRE) -- AquaBounty Technologies, Inc. (NASDAQ:AQB) ("AquaBounty" or the "Company"), a biotechnology company focused on enhancing productivity in the aquaculture market and a majority-owned subsidiary of Intrexon Corporation (NYSE:XON), announces the Company's financial results for the quarter ended September 30, 2017.

Financial and Operational Summary:

  • Commenced work on upgrades to the Indiana farm site to increase its capacity to 1200 metric tons;
  • completed renovations in Rollo Bay on the hatchery building and progressed construction activities on the 250-metric-ton production and broodstock buildings;
  • net loss for the nine-month period ended September 30, 2017, increased to $6.6 million from $5.8 million in the corresponding period of the previous year, reflecting investment in the Indiana farm site and Rollo Bay hatchery; and
  • cash and cash equivalents were $4.7 million (December 31, 2016: $3.3 million).

Ronald Stotish, Chief Executive Officer of AquaBounty, stated: "In this quarter, our primary focus has been on getting our Indiana farm site ready for FDA inspection. This is in advance of stocking the facility with AquAdvantage® Salmon eggs, which we hope will occur next spring. We also anticipate the construction of the production and broodstock buildings at our Rollo Bay farm site to be completed early next year."

Forward-Looking Statements:




For further information, please contact:

Dave Conley, Director of Communications
AquaBounty Technologies, Inc.
+1 613 294 3078

Market News and Data brought to you by Benzinga APIs

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

To add Benzinga News as your preferred source on Google, click here.


Posted In:
BiotechEarningsPress ReleasesGeneral
AQB Logo
AQBAquaBounty Technologies Inc
$0.8900-1.11%
Overview

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact contained in this press release are forward-looking statements, including statements regarding the potential for, progress toward, and possible timing for upgrading the Company's farm site in Indiana and constructing production and broodstock buildings in Rollo Bay; expected production capacities of the Company's facilities; progress in readying the Indiana farm site for FDA inspection and the possibility of the regulatory approval of that site by the FDA; and the potential for and timing of stocking that facility with AquAdvantage® Salmon eggs. Forward-looking statements may be identified with words such as "will," "may," "expect," "plan," "anticipate," "upcoming," "believe," "estimate," or similar terminology, and the negative of these terms. Forward-looking statements are not promises or guarantees of future performance and are subject to a variety of risks and uncertainties, many of which are beyond our control, which could cause actual results to differ materially from those contemplated in these forward-looking statements. Forward-looking statements speak only as of the date hereof, and, except as required by law, we undertake no obligation to update or revise these forward-looking statements. For additional information regarding these and other risks faced by us, please refer to our public filings with the Securities and Exchange Commission ("SEC"), available on the Investors section of our website at www.aquabounty.com and on the SEC's website at www.sec.gov.

AquaBounty Technologies, Inc.
Consolidated Balance Sheets
(Unaudited)
 
   As of
   September 30,December 31,
    2017  2016 
Assets   
Current assets:  
 Cash and cash equivalents$  4,717,821 $  3,324,609 
 Certificate of deposit 13,489  10,666 
 Other receivables 219,334  164,743 
 Inventory 78,499  - 
 Prepaid expenses and other assets 245,242  72,983 
 Total current assets 5,274,385  3,573,001 
     
Property, plant and equipment, net 19,478,853  1,723,707 
Definite lived intangible assets, net 188,421  198,698 
Indefinite lived intangible assets 191,800  191,800 
Other assets  162,093  21,628 
Total assets$  25,295,552 $  5,708,834 
     
Liabilities and stockholders' equity  
Current liabilities:  
 Accounts payable and accrued liabilities$  1,602,396 $  1,017,851 
 Current debt 55,223  17,913 
 Total current liabilities 1,657,619  1,035,764 
     
Long-term debt 3,059,990  2,645,015 
 Total liabilities 4,717,609  3,680,779 
     
Commitments and contingencies  
     
Stockholders' equity:  
 Common stock, $0.001 par value, 200,000,000 shares authorized; 
  8,895,094 (2016: 6,463,936) shares outstanding 8,895  6,464 
 Additional paid-in capital 126,681,495  101,581,724 
 Accumulated other comprehensive loss (243,188) (286,272)
 Accumulated deficit (105,869,259) (99,273,861)
Total stockholders' equity 20,577,943  2,028,055 
     
Total liabilities and stockholders' equity$  25,295,552 $  5,708,834 
      
      
 AquaBounty Technologies, Inc.
 Consolidated Statements of Operations and Comprehensive Loss
 (Unaudited)
      
   Three Months Ended Nine Months Ended
   September 30, September 30,
   20172016 20172016
Revenues      
 Product revenues$  - $  -  $  53,278 $  - 
        
Costs and expenses     
 Product costs -  -   50,777  - 
 Sales and marketing 195,947  209,556   607,145  650,075 
 Research and development 860,903  974,980   2,517,242  2,705,978 
 General and administrative 1,382,380  824,381   3,453,516  2,428,044 
 Total costs and expenses 2,439,230  2,008,917   6,628,680  5,784,097 
        
Operating loss (2,439,230) (2,008,917)  (6,575,402) (5,784,097)
        
Other income (expense)     
 Interest expense (5,597) (131,301)  (16,130) (238,940)
 Gain on disposal of equipment -  -   -  2,861 
 Other income (expense), net (1,392) (1,608)  (3,866) (4,463)
 Total other income (expense) (6,989) (132,909)  (19,996) (240,542)
        
Net loss $  (2,446,219)$  (2,141,826) $  (6,595,398)$  (6,024,639)
        
Other comprehensive income (loss):     
 Foreign currency translation gain (loss) 34,933  13,659   43,084  (86,516)
 Total other comprehensive income (loss) 34,933  13,659   43,084  (86,516)
        
Comprehensive loss$  (2,411,286)$  (2,128,167) $  (6,552,314)$  (6,111,155)
        
        
Basic and diluted net loss per share$  (0.28)$  (0.41) $  (0.76)$  (1.15)
Weighted average number of common shares -     
 basic and diluted 8,895,094  5,250,510   8,731,178  5,249,776 
        
AQB Logo
AQBAquaBounty Technologies Inc
$0.8900-1.11%
Overview
Comments
Loading...